UMU logo

PostDoc project (Drug Discovery and Cell-Autonomous Immunity)

PostDoc project (Drug Discovery and Cell-Autonomous Immunity)

This projects aims to identify and characterize small chemical compounds that can counteract growth of the obligate intracellular bacterial pathogen Chlamydia trachomatis either by activating cell-autonomous defense responses in infected cells or by repressing the pathogen’s ability to counteract these cellular defenses. The project is expected to provide deeper insights into mechanisms of host-pathogen interaction and to uncover starting points for the development of new host-directed or anti-virulence drugs.

Specific aims of the project include:

  • The development and optimization of an experimental protocol for high-throughput small compound screening.
  • The implementation of the screening and candidate validation.
  • The characterization of the mode of action of validated candidate compounds.

Interested? Please send me your CV and a short letter of motivation (preferentially as single PDF file) (email: This email address is being protected from spambots. You need JavaScript enabled to view it.)


 

PhD and PostDoc projects

We are constantly seeking highly motivated students and post-docs who would like to join our team. If you are interested in applying state-of-the-art tools in mo­lecular genetics to debunk the power of cell-autonomous immunity, please send me your CV and a short letter of motivation (preferentially as single PDF file) (email: This email address is being protected from spambots. You need JavaScript enabled to view it.).


 

Emmanuelle Charpentier:
MIMS is characterized by
ECharpentier about MIMS 2015 1

Emmanuelle Charpentier, Alumna at MIMS, now Director of the Max Planck Unit for the Science of Pathogens and Director of the Department of Regulation in Infection Biology, Max Planck Institute for Infection Biology, Berlin, Germany.

Link to the Emmanuelle Charpentier Lab

footer all slides 2014-02-06


Copyright © 2017 by The Laboratory for Molecular Infection Medicine Sweden (MIMS). All rights reserved.